Didanosine

"Didanosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.

Descriptor ID	D016049
MeSH Number(s)	D03.633.100.759.590.616.130 D13.570.230.500.090 D13.570.583.616.130 D13.570.800.573.130
Concept/Terms	Didanosine Didanosine Dideoxyinosine 2',3'-Dideoxyinosine 2',3' Dideoxyinosine ddI (Antiviral) Videx Videx NSC-612049 NSC-612049 NSC 612049 NSC612049

Below are MeSH descriptors whose meaning is more general than "Didanosine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Purines [D03.633.100.759]
Purine Nucleosides [D03.633.100.759.590]
Inosine [D03.633.100.759.590.616]
Didanosine [D03.633.100.759.590.616.130]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Deoxyribonucleosides [D13.570.230]
Dideoxynucleosides [D13.570.230.500]
Didanosine [D13.570.230.500.090]
Purine Nucleosides [D13.570.583]
Inosine [D13.570.583.616]
Didanosine [D13.570.583.616.130]
Ribonucleosides [D13.570.800]
Inosine [D13.570.800.573]
Didanosine [D13.570.800.573.130]

Below are MeSH descriptors whose meaning is related to "Didanosine".

Below are MeSH descriptors whose meaning is more specific than "Didanosine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Didanosine" by people in this website by year, and whether "Didanosine" was a major or minor topic of these publications.

Bar chart showing 8 publications over 8 distinct years, with a maximum of 1 publications in 1995 and 1997 and 2001 and 2002 and 2003 and 2005 and 2007 and 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1997	1	0	1
2001	0	1	1
2002	1	0	1
2003	1	0	1
2005	0	1	1
2007	1	0	1
2008	0	1	1

Below are the most recent publications written about "Didanosine" by people in Profiles.

Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb; 8(1):52-9.

View in: PubMed
McKinney RE, Rodman J, Hu C, Britto P, Hughes M, Smith ME, Serchuck LK, Kraimer J, Ortiz AA, Flynn P, Yogev R, Spector S, Draper L, Tran P, Scites M, Dickover R, Weinberg A, Cunningham C, Abrams E, Blum MR, Chittick GE, Reynolds L, Rathore M. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics. 2007 Aug; 120(2):e416-23.

View in: PubMed
Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J, Pomerantz RJ. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses. 2005 Sep; 21(9):768-75.

View in: PubMed
Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 1; 32(1):18-29.

View in: PubMed
Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JF. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. J Infect Dis. 2002 Oct 1; 186(7):1028-33.

View in: PubMed
Gougeon ML, Rouzioux C, Liberman I, Burgard M, Taoufik Y, Viard JP, Bouchenafa K, Capitant C, Delfraissy JF, Levy Y. Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients. AIDS. 2001 Sep 07; 15(13):1729-31.

View in: PubMed
Zhou XJ, Squires K, Pan-Zhou XR, Bernhard S, Agrofoglio L, Kirk M, Duchin KL, Sommadossi JP. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. J Clin Pharmacol. 1997 Mar; 37(3):201-13.

View in: PubMed
Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995 May; 1(5):417-22.

View in: PubMed
Jay C, Ropka M, Dalakas MC. The drugs 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy. J Acquir Immune Defic Syndr (1988). 1994 Jun; 7(6):630-1.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement